Company** | Product | Description | Indication | Status/Date | ||||||
Name | ||||||||||
CANCER | ||||||||||
Avax | O-Vax | Therapeutic vaccine; | Advanced ovarian | Presented results of on- | ||||||
Technologies Inc. | tumor cells removed | cancer | going Phase I/II trial at | |||||||
from patient, modified | 89th annual meeting of | |||||||||
with hapten (DNP; di- | the American Association | |||||||||
nitrophenyl), then | for Cancer Research | |||||||||
reinjected into patient | (AACR) in New Orleans | |||||||||
(along with cyclophos- | (3/31) | |||||||||
phamide) to stimulate | ||||||||||
patient's immune system | ||||||||||
AVI Biopharma | CTP-37 | Synthetic peptide conju- | Metastatic colorectal | Announced preliminary | ||||||
and Immuno- | Vaccine | gate vaccine designed to | cancer | results of Phase II trial | ||||||
Therapy Corp.* | elicit immune response | (3/26) | ||||||||
to human chorionic | ||||||||||
gonadotrophin | ||||||||||
Cell | Lisofylline | Compound designed to | To prevent or reduce | Primary endpoints were | ||||||
Therapeutics Inc. | inhibit production of | incidence of serious and | not met in 1st Phase III | |||||||
phosphatidic acid and | fatal infections, mucos- | trial (according to pre- | ||||||||
reduce oxidative dam- | itis and treatment- | liminary results) (3/25) | ||||||||
age (protects epithelial | related mortality in | |||||||||
cells from damage by | cancer patients with | |||||||||
free radicals; anti- | hematological malig- | |||||||||
inflammatory) | nancies undergoing | |||||||||
radiation and/or | ||||||||||
chemotherapy | ||||||||||
Cel-Sci Corp. | Multikine | Natural mixture of | Treatment of head and | Expanded ongoing clin- | ||||||
human cytokines, | neck cancer prior to | ical trials (at 4 Canadian | ||||||||
including interleukin-2 | surgery or radiation | sites) to include 2 U.S. | ||||||||
therapy | sites (3/17) | |||||||||
Coulter Pharma- | Bexxar | Murine monoclonal | Low-grade and trans- | Reached target enroll- | ||||||
ceutical Inc. | antibody against CD20 | formed low-grade non- | ment in pivotal Phase | |||||||
antigen on B cells; | Hodgkin's lymphoma in | trial (3/23) | ||||||||
radiolabeled with I-131 | patients who are refract- | |||||||||
ory to chemotherapy | ||||||||||
Endorex Corp. | ImmTher | Macrophage activator | Adjuvant therapy for | Initiated Phase II trial | ||||||
derived from muramyl | Ewing's sarcoma (bone | (3/17) | ||||||||
dipeptide (naturally | cancer in children) | |||||||||
occurring component | ||||||||||
of bacterial cell walls); | ||||||||||
designed to stimulate | ||||||||||
patient's immune system | ||||||||||
Imutec | Virulizin | Biological response | Advanced-stage pancre- | Completed patient en- | ||||||
Pharma Inc. | modifier extracted from | atic cancer in patients | lment in Phase I/II trial | |||||||
(TSE:IMT; Canada) | bovine reticuloendo- | who have failed prior | (3/11) | |||||||
thelium; activates | therapies | |||||||||
macrophages | ||||||||||
Ligand Pharma- | Panretin Gel | Chemically synthesized | Kaposi's sarcoma | Presented final analysis | ||||||
ceuticals Inc. | (LGD 1957) | version of 9-cis-retinoic | in AIDS patients | of Phase I/II trial (intra- | ||||||
acid (natural hormone | patient controlled study) | |||||||||
derived from vitamin A) | at American Academy of | |||||||||
(topical gel formulation) | Dermatology (AAD) | |||||||||
meeting in Orlando (3/1); | ||||||||||
reported final results of | ||||||||||
international, pivotal | ||||||||||
Phase III trial (3/26) | ||||||||||
Neoprobe Corp. | RIGScan | I-125-labeled mono- | Surgical detection and | Preliminary follow-up | ||||||
CR49 | clonal antibody for use | management of meta- | data on Phase III trial | |||||||
with hand-held isotope | static colorectal cancer | reported at 51st annual | ||||||||
detector for radioimmu- | Cancer Symposium of | |||||||||
noguided surgery | the Society of Surgical | |||||||||
Oncology in San Diego | ||||||||||
(3/31) | ||||||||||
NeoRx Corp. and | Avicidin | Multi-step process in | Metastatic prostate | Janssen initiated Phase II | ||||||
Janssen Pharma- | which a murine antibody | and colon cancers | trial (3/4) | |||||||
ceutica NV (Bel- | linked to strepavidin is | |||||||||
gium; subsidiary of | administered and allowed | |||||||||
Johnson & | to accumulate on surface | |||||||||
Johnson; NYSE:JNJ) | of tumor cells; then biotin | |||||||||
linked to yttrium-90 is | ||||||||||
administered, binding to | ||||||||||
strepavidin and killing | ||||||||||
tumor cells | ||||||||||
Onyx Pharma- | ONYX-015 | Genetically engineered | Recurrent and refractory | Initiated 3rd Phase II trial | ||||||
ceuticals Inc. | adenovirus that repli- | head and neck cancer | (aggressive treatment | |||||||
cates in and kills tumor | regimen) (3/13) | |||||||||
cells deficient in p53 | ||||||||||
tumor suppressor gene | ||||||||||
product | ||||||||||
Pharmacyclics | Gd-Tex | Radiation sensitizer | Radiation treatment for | Completed patient en- | ||||||
Inc. | gadolinium texaphyrin | brain metastases | rollment in Phase II trial | |||||||
(synthetic molecule) | (3/10) | |||||||||
coupled with photo- | ||||||||||
sensitizing agent | ||||||||||
Progenics Pharm- | MGV | Cancer vaccine; com- | High-risk melanoma | Presented initial results | ||||||
aceuticals Inc. | bines cancer antigens | and sarcoma | of Phase I/II trials at | |||||||
GD2 and GM2, separ- | AACR meeting (3/31) | |||||||||
ately coupled to carrier | ||||||||||
protein keyhole limpet | ||||||||||
hemocyanin (KLH) | ||||||||||
and mixed with QS-21 | ||||||||||
adjuvant | ||||||||||
Ribi | Melacine | Therapeutic cancer | Combination therapy | Data Safety and Monitor- | ||||||
ImmunoChem | vaccine made of lysed | with Intron A (inter- | ing Board recommended | |||||||
Research Inc. and | cells from 2 human mela- | feron alpha-2b) for | continuing pivotal Phase | |||||||
Schering-Plough | noma cell lines with a | treating Stage IV malig- | III trial (1st interim | |||||||
Corp. (NYSE:SGP) | broad array of melanoma | nant melanoma | review of data) (3/25) | |||||||
antigens, combined with | ||||||||||
Ribi's Detox adjuvant | ||||||||||
(contains monophos- | ||||||||||
phoryl lipid A and myco- | ||||||||||
bacterial cell-wall | ||||||||||
skeleton) | ||||||||||
Schering-Plough | rAd/p53 | Gene therapy; recombi- | Various types of cancer, | Presented data from on- | ||||||
Research Institute | nant adenovirus encod- | including metastatic | going Phase I trials at the | |||||||
and Canji Inc. (units | ing human p53 tumor | colon, ovarian, head and | AACR meeting (3/31) | |||||||
of Schering-Plough | suppressor gene | neck, non-small lung | ||||||||
Corp.; NYSE:SGP) | cancer and melanoma | |||||||||
Sequus Pharma- | SPI-077 | Long-circulating Stealth | Solid tumors, including | Presented data from on- | ||||||
ceuticals Inc. | liposome formulation | non-small cell lung | going Phase I trial at the | |||||||
of cisplatin | cancer | AACR meeting (3/31) | ||||||||
Targeted | E1A Gene | E1A tumor suppressor | Metastatic or recurrent | Presented preliminary | ||||||
Genetics Corp. | Therapy | gene product; consists of | breast and ovarian | results of 2 Phase I trials | ||||||
(tgDCC-E1A) | E1A gene formulated in | cancers | at the AACR meeting | |||||||
lipid-based gene delivery | (3/30) | |||||||||
system; intratumoral | ||||||||||
injection | ||||||||||
Techniclone | Oncolym | LYM-1 murine mono- | Intermediate- and high- | Initiated Phase II/III trial | ||||||
Corp. | clonal antibody to HLA- | grade refractory or | (3/30) | |||||||
DR10 protein (cell- | relapsed non-Hodgkin's | |||||||||
surface marker present | B-cell lymphoma | |||||||||
on 80% of lymphoma | ||||||||||
cells), labeled with I-131 | ||||||||||
Techniclone | TNT | Tumor necrosis therapy; | Malignant glioma | Initiated Phase I trial | ||||||
Corp. and Cam- | chimeric monoclonal | (brain tumor; inter- | (3/31) | |||||||
bridge Antibody | antibody that targets | stitial delivery | ||||||||
Technology Ltd. | DNA-associated histone | system) | ||||||||
antigens, labeled with | ||||||||||
I-131 (targets necrotic | ||||||||||
center of tumor) | ||||||||||
Wisconsin | POH | Perillyl alcohol (syn- | Advanced carcinomas | Initiated enrollment in | ||||||
Genetics Inc. | thetic monoterpene) | of the breast, ovary and | 3 Phase II trials (spon- (wholly owned sub- | |||||||
prostate | sored by the National | |||||||||
sidiary of Endorex | Cancer Institute) (3/3) | |||||||||
Corp.) | ||||||||||
CARDIOVASCULAR | ||||||||||
Alliance Pharma- | Imagent | Contrast agent; aqueous | To improve echocardio- | Initiated Phase III trials | ||||||
ceutical Corp. and | dispersion of micro- | grams performed to test | (3/31) | |||||||
Schering AG | bubbles containing mix- | cardiac function | ||||||||
(Germany) | ture of perfluoro-chemi- | |||||||||
cal vapor and a physio- | ||||||||||
logical gas | ||||||||||
Baxter Healthcare | HemAssist | Blood substitute; | Severe traumatic | Terminated Phase III | ||||||
Corp. (subsidiary of | diaspirin cross-linked | hemorrhagic shock | trail after interim | |||||||
Baxter Interna- | hemoglobin (made from | review of data by Data | ||||||||
tional Inc.; | unused human donor | Monitoring Committee | ||||||||
NYSE:BAX) | blood) | showed that patients in | ||||||||
treatment group had in- | ||||||||||
creased mortality com- | ||||||||||
pared to controls (3/31) | ||||||||||
Centocor Inc. | ReoPro | Chimeric monoclonal | To enhance effective- | Preliminary results of | ||||||
and Eli Lilly & Co. | (FDA- | antibody fragment to | ness of coronary stents | EPILOG Stent Phase III | ||||||
(NYSE:LLY) | approved) | GPIIb/IIIa platelet | in angioplasty patients | trial reported at meeting | ||||||
receptor | being treated for coro- | of American College of | ||||||||
nary artery disease | Cardiology (ACC) in | |||||||||
(to reduce ischemic | Atlanta (3/31) | |||||||||
complications) | ||||||||||
Cypress | Cyplex | Infusible platelet | To control bleeding in | Initiated expanded Phase | ||||||
Bioscience Inc. | membranes (manufac- | patients with low levels | II trial (3/30) | |||||||
tured from human | of circulating platelets | |||||||||
platelets, which are | (secondary to chemo- | |||||||||
heat treated and | therapy and/or radiation | |||||||||
lyophilized) | therapy) | |||||||||
CytRx Corp. | Flocor | Purified poloxamer | Vascular occlusive | Initiated Phase III trials | ||||||
188; surfactant molecule | crisis in sickle cell | (3/18) | ||||||||
that alters the way cells | disease | |||||||||
and molecules interact | ||||||||||
with water | ||||||||||
Epix Medical Inc. | MS-325 | MRI contrast agent; | Enhancement of cardio- | Completed patient enrol- | ||||||
and Mallinckrodt | magnetically active, | logy imaging in evalua- | lment in Phase II trial | |||||||
Inc. (NYSE:MKG) | injectable small mole- | tion of peripheral | (3/12) | |||||||
cule that binds to | vascular disease | |||||||||
albumin | ||||||||||
Genentech Inc. | VEGF | Genetically engineered | To promote blood ves- | Small clinical study per- | ||||||
vascular endothelial | sel growth around | formed at Hennepin | ||||||||
growth factor (VEGF) | blockages in coronary | County Medical Center | ||||||||
infused into coronary | arteries in patients | in Minneapolis using | ||||||||
artery | with severe heart | Genentech's VEGF | ||||||||
disease | protein product; results | |||||||||
presented at ACC meet- | ||||||||||
ing (3/30) | ||||||||||
Immunex Corp. | Enbrel | Recombinant, soluble | Congestive heart failure | Initiated Phase I trial | ||||||
p75 tumor necrosis | (3/31) | |||||||||
factor receptor (TNFr) | ||||||||||
linked to the Fc portion | ||||||||||
of human IgG1 | ||||||||||
CENTRAL NERVOUS SYSTEM | ||||||||||
Neurex Corp. | Ziconotide | Selective N-type neuron- | Chronic malignant pain | Completed patient enrol- | ||||||
(formerly | specific calcium channel | caused by cancer or | lment in Phase III trial; | |||||||
SNX-111) | blocker (derived from | AIDS | trial halted early be- | |||||||
snail toxin) | cause independent anal- | |||||||||
ysis indicated statisti- | ||||||||||
cally significant results | ||||||||||
(3/31) | ||||||||||
DIABETES | ||||||||||
Alteon Inc. and | Pimagedine | Compound designed to | Treatment of Type I | Safety Monitoring Com- | ||||||
Genentech Inc. | block abnormal glucose/ | diabetics with overt | mittee recommended | |||||||
protein complexes | nephropathy (ACTION I | continuation of ACTION I | ||||||||
(advanced glycosylation | trial) and treatment of | Phase III trial but cessa- | ||||||||
end-products) that lead | Type II diabetics with | tion of ACTION II Phase | ||||||||
to diabetic complica- | overt nephropathy | III trial, in which there | ||||||||
tions | (ACTION II trial) | was increased incidence | ||||||||
of side effects (3/18); | ||||||||||
FDA concurred with both | ||||||||||
recommendations | ||||||||||
(3/23) | ||||||||||
INFECTION | ||||||||||
Enzo | HGTV43 | Genetic antisense | To stop viral progres- | FDA cleared protocol | ||||||
Therapeutics Inc. | medicine; insertion of | sion in HIV-infected | for Phase I trial (3/31) | |||||||
(subsidiary of | gene that synthesizes | patients | ||||||||
Enzo Biochem | antisense molecule to | |||||||||
Inc.) | HIV-1 directly into | |||||||||
blood cells (patient's | ||||||||||
stem cells treated ex | ||||||||||
vivo to render them | ||||||||||
HIV-resistant, then | ||||||||||
reinfused into patient) | ||||||||||
Progenics | PRO 542 | Fusion protein that | HIV infection in adults | Presented initial results | ||||||
Pharmaceuticals | incorporates HIV- | with measurable circu- | of Phase I/II trial at the | |||||||
Inc. | binding region of | lating virus | Keystone Symposium | |||||||
cell surface receptor | on HIV Pathogenesis | |||||||||
into a human antibody | and Treatment in Park | |||||||||
molecule | City, Utah (3/17) | |||||||||
Shaman Pharma- | Provir | Oral formulation of | Diarrhea in AIDS | Initiated enrollment in | ||||||
ceuticals Inc. | compound SP-303, | patients | pivotal Phase III trial | |||||||
which is isolated from | (being conducted in U.S. | |||||||||
the croton plant; it is | and Puerto Rico) (3/30) | |||||||||
thought to act by | ||||||||||
inhibiting secretion of | ||||||||||
chloride from intestinal | ||||||||||
cells | ||||||||||
MISCELLANEOUS | ||||||||||
Anergen Inc. | AnervaX | Therapeutic peptide | Rheumatoid arthritis | Completed analysis of | ||||||
vaccine; synthetic | Phase IIa trial (3/5) | |||||||||
20-amino-acid peptide | ||||||||||
that targets DR4 and | ||||||||||
DR1 human leukocyte | ||||||||||
antigen (HLA) mole- | ||||||||||
cules; interferes with | ||||||||||
activation of T cells | ||||||||||
Cellegy Pharma- | Glylorin | Monolaurin | Non-bullous congeni- | Announced that the pro- | ||||||
ceuticals Inc. and | tal ichthyosiform | duct did not achieve sta- | ||||||||
Glaxo Wellcome | erythroderma | tistical significance | ||||||||
plc (NYSE:GLX; U.K.) | in its primary outcome | |||||||||
variable in a Phase III | ||||||||||
trial conducted by | ||||||||||
Glaxo Wellcome (3/4) | ||||||||||
Creative | OP-1 | Device that combines | Bone graft; to induce | Clinical trial data, demon- | ||||||
Biomolecules | Device | genetically engineered | normal bone regenera- | strating that treatment is | ||||||
Inc. and Stryker | bone morphogenic pro- | tion in tibial non-union | equivalent to autograft- | |||||||
Corp. (NYSE:SYK) | tein (OP-1) with resorb- | fractures | ing were presented at | |||||||
able collagen scaffold | American Academy of | |||||||||
that is surgically | Orthopedic Surgeons | |||||||||
implanted in bone | (AAOS)meeting in | |||||||||
fractures and defects | New Orleans (3/23) | |||||||||
Discovery | ST-630 | Biologically active | Post-menopausal | Completed Phase Ia trial | ||||||
Laboratories Inc. | analogue of vitamin D | osteoporosis | (3/24) | |||||||
in softgel capsules | ||||||||||
Discovery | SuperVent | Tyloxapol (non-anionic | Cystic fibrosis | Completed Phase I/IIa | ||||||
Laboratories Inc. | Aerosol | alkylaryl and polyether | open-label trial (3/31) | |||||||
Solution | alcohol) | |||||||||
Dura Pharma- | Albuterol | Powder aerosol form- | Asthma | Results of 2 clinical | ||||||
ceuticals Inc. and | Spiros | ulation of albuterol | studies presented at | |||||||
Spiros Develop- | delivered to lungs via | American Academy of | ||||||||
ment Corp. II Inc. | Spiros inhaler | Allergy, Asthma and | ||||||||
(NASDAQ:SDCOZ) | Immunology (AAAAI) | |||||||||
annual meeting in Wash- | ||||||||||
ington (3/16) | ||||||||||
Gliatech Inc. | Adcon-L | Anti-adhesion barrier | To inhibit postopera- | New clinical findings pre- | ||||||
gel (semisynthetic | tive adhesions involving | sented at AAOS meeting | ||||||||
carbohydrate polymer) | spinal cord and nerve | (3/19) | ||||||||
roots following back | ||||||||||
surgery | ||||||||||
Gliatech Inc. | Adcon-L | Anti-adhesion barrier | To inhibit postopera- | Pivotal clinical trial re- | ||||||
gel (semisynthetic | tive peridural scars | sults published in 3/98 | ||||||||
carbohydrate polymer) | (following lumbar | issue of The American | ||||||||
disc surgery) | Journal of Orthopedics | |||||||||
(3/4) | ||||||||||
Icos Corp. | rPAF-AH | Human recombinant | To decrease incidence | Initiated Phase II trial | ||||||
platelet-activating | and severity of post- | (3/16) | ||||||||
factor (PAF) acetyl- | endoscopic retrograde | |||||||||
hydrolase; regulates | cholangiopancrea- | |||||||||
levels of PAF by con- | tography (ERCP) | |||||||||
verting it to inactive | pancreatitis | |||||||||
form | ||||||||||
Immunex Corp. | Enbrel | Recombinant, soluble | Juvenile rheumatoid | Presented preliminary | ||||||
p75 tumor necrosis | arthritis | results of clinical trial at | ||||||||
factor receptor (TNFr) | the American Academy | |||||||||
linked to the Fc portion | of Pediatrics' Pediatric | |||||||||
of human IgG1 | Rheumatology Into The | |||||||||
Next Century meeting in | ||||||||||
Park City, Utah (3/15) | ||||||||||
Immunex Corp. | Nuvance | Soluble interleukin-4 | Moderate asthma | Presented results of pilot | ||||||
(IL-4) receptor; blocks | study at AAAAI meeting | |||||||||
binding of IL-4 to its | (3/14) | |||||||||
receptor on surface of | ||||||||||
B and T cells | ||||||||||
InKine Pharma- | CBP-1011 | Oral glucocorticoid | Idiopathic thrombo- | FDA accepted protocol | ||||||
ceutical Co. Inc. | analogue | cytopenic purpura | amendments for Phase | |||||||
III trial (broadens patient | ||||||||||
enrollment parameters | ||||||||||
and changes dosing regi- | ||||||||||
men) (3/24) | ||||||||||
Life Medical | Repel-CV | Bioresorbable, polymer- | Prevention of post- | FDA approved investiga- | ||||||
Sciences Inc. | based adhesion barrier | operative adhesions | tional device exemption | |||||||
(NASDAQ:CHAI) | film | in cardiovascular | for pilot clinical trial | |||||||
surgery | (3/23) | |||||||||
Sonus Pharma- | EchoGen | Fluorocarbon-based | Contrast radiography | Completed enrollment in | ||||||
ceuticals Inc. | Emulsion | ultrasound contrast | in transrectal ultra- | international Phase III | ||||||
agent | sonography of prostate | trial (3/24) | ||||||||
Transcend Thera- | Procysteine | Product that delivers | Acute respiratory | Safety Monitoring Board | ||||||
peutics Inc. and | I.V. | cysteine into cells to | distress syndrome | completed interim safety | ||||||
Boehringer Ingel- | neutralize tissue-damag- | evaluation of data from | ||||||||
heim Interna— | ing reactive oxygen | 150 patients in Phase III | ||||||||
tional (Germany) | species by boosting | trial and recommended | ||||||||
cellular production of | continuation of trial | |||||||||
glutathione | (3/11); however, after it | |||||||||
had reviewed data on 213 | ||||||||||
patients, it found that the | ||||||||||
incidence of all-cause | ||||||||||
mortality was higher in | ||||||||||
treatment group than the | ||||||||||
placebo and thus the | ||||||||||
Phase III trial was suspen- | ||||||||||
ded (3/20) | ||||||||||
Transkaryotic | — | Alpha-galactosidase A | Protein replacement | Presented results of | ||||||
Therapies Inc. | (alpha-gal, a lysosomal | product for treating | Phase I trial (conducted | |||||||
enzyme) | Fabry disease | at the National Institutes | ||||||||
of Health) at the 5th | ||||||||||
Joint Clinical Genetics | ||||||||||
meeting in Los Angeles | ||||||||||
(3/1) | ||||||||||
NOTES: | ||||||||||
TSE = Toronto Stock Exchange | ||||||||||
* Private companies are indicated with an asterisk. | ||||||||||
** Unless otherwise noted, the trading symbols for public biotechnology companies can be found by referring to the BioWorld Stock Report For Public Biotechnology Companies on pp. 11-12. |